Seres Therapeutics, Inc. (MCRB) Return on equity 2016–2025
Seres Therapeutics, Inc. (MCRB) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
12.9%FY2025 · since FY2016: -69.0% → 12.9%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 12.9% | +11.9 pp |
| FY2024 | 1.0% | — |
| FY2022 | -2319.9% | -2270.1 pp |
| FY2021 | -49.9% | +1.1 pp |
| FY2020 | -51.0% | — |
| FY2017 | -147.3% | -78.2 pp |
| FY2016 | -69.0% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More MCRB financial trends
MCRB RevenueMCRB Net incomeMCRB Net marginMCRB Gross profitMCRB Gross marginMCRB Operating incomeMCRB Operating marginMCRB Operating cash flowMCRB Free cash flowMCRB Capital expendituresMCRB Stock buybacksMCRB Dividends paidMCRB Total assetsMCRB Total liabilitiesMCRB Shareholders’ equityMCRB overview →